{
  "meta": {
    "title": "64_The_Breast",
    "url": "https://brainandscalpel.vercel.app/64-the-breast-8c21e5e7.html",
    "scrapedAt": "2025-11-30T12:33:58.479Z"
  },
  "questions": [
    {
      "text": "Which of the following lesions does not arise from the terminal duct lobular unit of the breast?",
      "choices": [
        {
          "id": 1,
          "text": "Sclerosing adenosis"
        },
        {
          "id": 2,
          "text": "Blue dome cyst"
        },
        {
          "id": 3,
          "text": "Carcinoma breast"
        },
        {
          "id": 4,
          "text": "Periductal mastitis"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Periductal mastitis</strong>&nbsp;arises from the <strong>large</strong> <strong>lactiferous ducts</strong>.</p>\n<p>It is also known as <strong>squamous metaplasia</strong> of lactiferous ducts,&nbsp;recurrent subareolar abscess, or <strong>Zuska disease</strong>.</p>\n<p>The<strong> terminal duct lobular unit </strong>(TDLU) is&nbsp;the basic functional and histopathological unit of the breast. Successive branching of large ducts eventually leads to the TDLU.&nbsp;Sclerosing adenosis, blue dome cyst, and carcinoma breast&nbsp;arise from the TDLU.</p><hr><h3>Related Pearl: Anatomic Origins of Common Breast Lesions</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b52f182ae9ef4e41a63d4c52bf8469dbx1280x1413.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5646",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following lesions arise from the large ducts of the breast?<div class='question-desc-html'><ol>\n<li>Duct ectasia</li>\n<li>Fibroadenoma</li>\n<li>Paget's disease</li>\n<li>Atypical hyperplasia</li>\n<li>Phyllodes tumor</li>\n</ol></div>",
      "choices": [
        {
          "id": 1,
          "text": "3 and 5"
        },
        {
          "id": 2,
          "text": "1 and 5"
        },
        {
          "id": 3,
          "text": "2 and 4"
        },
        {
          "id": 4,
          "text": "1 and 3"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Duct ectasia</strong> and&nbsp;<strong>Paget's</strong> disease&nbsp;arise from the <strong>large ducts</strong> of the breast.</p>\n<p>Normal anatomy of the breast includes ducts, lobules, and stroma. Successive branching of the large ducts eventually leads to the terminal duct lobular unit.</p>\n<p><strong>Atypical hyperplasia</strong> arises from the <strong>terminal ducts</strong> and lobules, whereas,&nbsp;<strong>fibroadenoma</strong> and&nbsp;<strong>phyllodes</strong> tumors arise from the <strong>intralobular stroma</strong>.</p><hr><h3>Related Pearl: Anatomic Origins of Common Breast Lesions</h3><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/b52f182ae9ef4e41a63d4c52bf8469dbx1280x1413.JPEG\" alt=\"Pearl Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5647",
      "difficulty": "medium"
    },
    {
      "text": "A 28-year-old lactating mother presents with pain in her left breast. On examination, you notice her nipple is erythematous and tender with a purulent exudate. Which of the following is the most common cause of this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Pseudomonas aeruginosa"
        },
        {
          "id": 2,
          "text": "Streptococcus viridans"
        },
        {
          "id": 3,
          "text": "Streptococcus pneumoniae"
        },
        {
          "id": 4,
          "text": "Staphylococcus aureus"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario is suggestive of <strong>acute mastitis. </strong>The most common cause of acute mastitis is<strong>&nbsp;<em>Staphylococcus aureus</em></strong>.</p>\n<p>Acute bacterial mastitis typically occurs during the <strong>1st month of breastfeeding </strong>(lactational breast abscess). It is caused by a local bacterial infection when the breast is most vulnerable due to cracks and fissures in the nipples.</p>\n<p>Staphylococcal acute mastitis typically results in&nbsp;<strong>localized abscesses</strong>.</p>\n<p>Option A: Breast abscess caused by <em>Pseudomonas aeruginosa</em> is uncommon, only a few cases have been documented in immunocompromised patients.</p>\n<p>Options B and C:&nbsp;Streptococcal infections tend to spread throughout the breast in the form of <strong>cellulitis</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5648",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following diseases is most strongly associated with a history of smoking?",
      "choices": [
        {
          "id": 1,
          "text": "Granulomatous mastitis"
        },
        {
          "id": 2,
          "text": "Fat necrosis"
        },
        {
          "id": 3,
          "text": "Periductal mastitis"
        },
        {
          "id": 4,
          "text": "Carcinoma breast"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Periductal mastitis</strong>&nbsp;is strongly associated with a history of <strong>smoking</strong>.&nbsp;More than 90% of the affected individuals are smokers.&nbsp;</p>\n<p>Periductal mastitis is also called recurrent subareolar abscess or squamous metaplasia of lactiferous ducts or<strong> Zuska disease</strong>. In this condition, a&nbsp;relative <strong>deficiency of vitamin A</strong> associated with smoking or toxic substances in tobacco smoke alters the differentiation of the ductal epithelium.</p>\n<p>Histologically, there is&nbsp;keratinizing<strong> squamous metaplasia </strong>of the nipple ducts. Keratin shed from these cells is trapped and plugs (<strong>keratin</strong> <strong>plug</strong>) the ductal system, causing dilation and eventually rupture of the duct. This results in keratin spillage into the surrounding periductal tissue forming a&nbsp;<strong>chronic granulomatous </strong>inflammatory response.</p>\n<p>It presents with a painful erythematous subareolar mass that clinically <strong>mimics bacterial abscess</strong>. It&nbsp;has&nbsp;a high recurrence rate.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/cce8b05b5a774bb68f4c0aacbfbede00x1280x2244.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5650",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old woman presented with a painless palpable lump in her left breast. She had sustained a traumatic blow to her left breast 1 month back. Mammography showed a radiolucent cystic lesion with rimmed calcification. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Lymphocytic mastopathy"
        },
        {
          "id": 2,
          "text": "Sclerosing adenosis"
        },
        {
          "id": 3,
          "text": "Fat necrosis"
        },
        {
          "id": 4,
          "text": "Hyalinized fibroadenoma"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The typical history of a breast lump following <strong>trauma</strong> and mammography findings of&nbsp;a <strong>radiolucent</strong> <strong>cystic</strong> lesion with <strong>rimmed calcification&nbsp;</strong>suggests a diagnosis of<strong>&nbsp;fat necrosis</strong>.</p>\n<p>About half the affected women with fat necrosis of the breast have a history of breast trauma or previous surgery. It&nbsp;can present as a <strong>painless</strong> palpable mass, skin thickening or retraction, or mammographic densities or calcifications.</p>\n<p>Histologically, necrotic adipose tissue with <strong>foamy macrophages</strong>, multinucleated <strong>giant cells</strong>,&nbsp;and chronic inflammatory cells are seen often with <strong>hemosiderin</strong> deposits, <strong>fibrosis</strong>,&nbsp;and calcification.</p>\n<p>The following image shows an area of fat necrosis within breast tissue.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/dc7a21d3c4f84155b98928926dd960ebx766x599.JPEG\" alt=\"Explanation Image\"><p><strong>Note:</strong>&nbsp;Calcifications are seen on mammography in the following conditions -</p>\n<ul>\n<li>Apo&shy;crine cysts</li>\n<li>Hyalinized fibroadenomas</li>\n<li>Sclerosing adenosis</li>\n<li>Duct ectasia&nbsp;</li>\n<li>Breast carcinoma- shows <strong>irregular densities</strong>&nbsp;and small, numerous, clustered calcification (<strong>microcalcifications</strong>).</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5651",
      "difficulty": "easy"
    },
    {
      "text": "Which of the following is a proliferative breast lesion?",
      "choices": [
        {
          "id": 1,
          "text": "Papilloma"
        },
        {
          "id": 2,
          "text": "Cysts"
        },
        {
          "id": 3,
          "text": "Mild hyperplasia"
        },
        {
          "id": 4,
          "text": "Adenosis"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Papillomas</strong> are classified under <strong>proliferative </strong>breast diseases<strong> without atypia</strong>.</p>\n<p>Proliferative breast lesions without atypia are not clonal and usually have <strong>no genetic changes</strong>. Thus they are predictors of risk but are not true precursors of carcinoma.</p>\n<p><strong>Benign</strong> <strong>epithelial lesions</strong> are classified into <strong>three groups</strong>, according to the subsequent risk of developing breast cancer. These are:</p>\n<div class=\"page\" title=\"Page 1052\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Non-proliferative breast changes</li>\n<li>Proliferative breast disease without atypia</li>\n<li>Atypical hyperplasia</li>\n</ul>\n<p>Note:<strong>&nbsp;</strong>Lobular carcinoma in situ (<strong>LCIS</strong>) has recently been classified as a&nbsp;<strong>benign</strong>&nbsp;lesion with associated risk for developing carcinoma in the future but not as a malignancy capable of metastases.</p>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Epithelial Lesions and Risk of Malignancy</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Pathologic Lesions and Relative Risk of Malignancy</strong></p>\n</td>\n<td>\n<p><strong>Examples&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Non-proliferative Breast Changes / Fibrocystic changes</strong></p>\n<p>(RR = 1)</p>\n</td>\n<td>\n<ul>\n<li>Duct ectasia</li>\n<li>Cysts</li>\n<li>Apocrine change</li>\n<li>Mild hyperplasia</li>\n<li>Adenosis</li>\n<li>Fibroadenoma without complex features</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Proliferative Disease Without Atypia</strong></p>\n<p>(RR = 1.5 to 2)</p>\n</td>\n<td>\n<ul>\n<li>Moderate or florid hyperplasia</li>\n<li>Sclerosing adenosis</li>\n<li>Papilloma</li>\n<li>Complex sclerosing lesion (radial scar)</li>\n<li>Fibroadenoma with complex features</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Proliferative Disease with Atypia</strong></p>\n<p>(RR = 4 to 5)</p>\n</td>\n<td>\n<ul>\n<li>Atypical ductal hyperplasia (ADH)</li>\n<li>Atypical lobular hyperplasia (ALH)</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Carcinoma in situ</strong></p>\n<p>(RR = 8 to 10)</p>\n</td>\n<td>\n<ul>\n<li>Lobular carcinoma in situ (LCIS)</li>\n<li>Ductal carcinoma in situ (DCIS)</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5653",
      "difficulty": "medium"
    },
    {
      "text": "All of the following lesions are proliferative breast lesions without atypia except:",
      "choices": [
        {
          "id": 1,
          "text": "Duct ectasia"
        },
        {
          "id": 2,
          "text": "Radial scar"
        },
        {
          "id": 3,
          "text": "Sclerosing adenosis"
        },
        {
          "id": 4,
          "text": "Florid hyperplasia"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>Duct ectasia</strong> is a<strong> non-proliferative</strong> breast change.</p>\n<p>Radial scar, sclerosing adenosis, and florid hyperplasia belong to proliferative breast lesions without atypia.</p>\n<p>Proliferative breast lesions without atypia are not clonal and are not commonly found to have genetic changes. Thus they are predictors of risk but unlikely to be true precursors of carcinoma.</p><hr><h3>Related Pearl: Epithelial Lesions and Risk of Malignancy</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Pathologic Lesions and Relative Risk of Malignancy</strong></p>\n</td>\n<td>\n<p><strong>Examples&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Non-proliferative Breast Changes / Fibrocystic changes</strong></p>\n<p>(RR = 1)</p>\n</td>\n<td>\n<ul>\n<li>Duct ectasia</li>\n<li>Cysts</li>\n<li>Apocrine change</li>\n<li>Mild hyperplasia</li>\n<li>Adenosis</li>\n<li>Fibroadenoma without complex features</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Proliferative Disease Without Atypia</strong></p>\n<p>(RR = 1.5 to 2)</p>\n</td>\n<td>\n<ul>\n<li>Moderate or florid hyperplasia</li>\n<li>Sclerosing adenosis</li>\n<li>Papilloma</li>\n<li>Complex sclerosing lesion (radial scar)</li>\n<li>Fibroadenoma with complex features</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Proliferative Disease with Atypia</strong></p>\n<p>(RR = 4 to 5)</p>\n</td>\n<td>\n<ul>\n<li>Atypical ductal hyperplasia (ADH)</li>\n<li>Atypical lobular hyperplasia (ALH)</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Carcinoma in situ</strong></p>\n<p>(RR = 8 to 10)</p>\n</td>\n<td>\n<ul>\n<li>Lobular carcinoma in situ (LCIS)</li>\n<li>Ductal carcinoma in situ (DCIS)</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5655",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common clinical presentation seen in patients with duct papilloma?",
      "choices": [
        {
          "id": 1,
          "text": "Retraction of nipple"
        },
        {
          "id": 2,
          "text": "Painless lump"
        },
        {
          "id": 3,
          "text": "Bloody nipple discharge"
        },
        {
          "id": 4,
          "text": "Eczema and itching of nipple"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The most common clinical presentation seen in patients with duct papilloma is <strong>nipple discharge</strong>.&nbsp;More than 80% of large duct papillomas produce a nipple discharge.&nbsp;</p>\n<p>Papillomas grow within a <strong>dilated duct</strong> and are composed of multiple branching <strong>fibrovascular cores</strong>. It can be serous or bloody.</p>\n<ul>\n<li><strong>Serous </strong>discharge - due to&nbsp;<strong>intermittent blockage</strong> and release of normal breast secretions or irritation of the duct by the papilloma</li>\n<li><strong>Bloody</strong> discharge - due to <strong>torsion</strong> of the stalk, causing infarction</li>\n</ul><hr><h3>Related Pearl: Discharge from the Nipple</h3><p><strong>From the surface:</strong></p>\n<ul>\n<li>Paget&rsquo;s disease</li>\n<li>Skin diseases (eczema, psoriasis)</li>\n<li>Rare causes (e.g., chancre)</li>\n</ul>\n<p><strong>From a single duct:</strong></p>\n<ul>\n<li><strong>Blood-stained:</strong>\n<ul>\n<li>Intraductal papilloma (M/C cause)</li>\n<li>Intraductal carcinoma</li>\n<li>Duct ectasia</li>\n</ul>\n</li>\n<li><strong>Serous (any colour):</strong>\n<ul>\n<li>Fibrocystic disease</li>\n<li>Duct ectasia</li>\n<li>Carcinoma</li>\n</ul>\n</li>\n</ul>\n<p><strong>From multiple ducts:</strong></p>\n<ul>\n<li><strong>Blood-stained:</strong>\n<ul>\n<li>Carcinoma (M/C cause)</li>\n<li>Ectasia</li>\n<li>Fibrocystic disease</li>\n</ul>\n</li>\n<li><strong>Black or green:</strong>\n<ul>\n<li>Duct ectasia</li>\n</ul>\n</li>\n<li><strong>Purulent:</strong>\n<ul>\n<li>Infection</li>\n</ul>\n</li>\n<li><strong>Serous:</strong>\n<ul>\n<li>Fibrocystic disease (M/C cause)</li>\n<li>Duct ectasia</li>\n<li>Carcinoma</li>\n</ul>\n</li>\n<li><strong>Milk:</strong>\n<ul>\n<li>Lactation</li>\n<li>Rare causes (hypothyroidism, pituitary tumour)</li>\n</ul>\n</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5656",
      "difficulty": "medium"
    },
    {
      "text": "A young man presents to your clinic with the following finding. Which of the following is not associated with this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Klinefelter syndrome"
        },
        {
          "id": 2,
          "text": "Seminoma"
        },
        {
          "id": 3,
          "text": "Sertoli cell tumor"
        },
        {
          "id": 4,
          "text": "Alcohol"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The image given depicts <strong>gynecomastia</strong>. Seminoma is not a cause of this condition.</p>\n<p>Gynecomastia occurs due to increased estrogenic action.&nbsp;The most<strong> common causes </strong>of gynecomastia include:&nbsp;</p>\n<ul>\n<li>Cirrhosis of the liver</li>\n<li><strong>Alcohol</strong></li>\n<li>Marijuana, heroin</li>\n<li>Antiretroviral therapy</li>\n<li>Anabolic steroids</li>\n<li><strong>Klinefelter</strong> syndrome (XXY karyotype)</li>\n<li>Functioning testicular neoplasms such as Leydig cell or <strong>Sertoli cell tumors</strong></li>\n</ul>\n<p>Microscopically, there is an increase in the&nbsp;<strong>dense collagenous connective tissue</strong>. It is associated with <strong>epithelial hyperplasia</strong> of the duct lining with characteristic tapering micro-papillae.&nbsp;Lobule formation is almost never observed.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/69b11b2abeca4296b36144a4664333b8.PNG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5657",
      "difficulty": "medium"
    },
    {
      "text": "A biopsy was performed on a female patient who presented with a lump in her right breast. Presence of which of the following findings is not associated with an increased risk of cancer?",
      "choices": [
        {
          "id": 1,
          "text": "Florid hyperplasia"
        },
        {
          "id": 2,
          "text": "Fibroadenoma with complex features"
        },
        {
          "id": 3,
          "text": "Sclerosing adenosis"
        },
        {
          "id": 4,
          "text": "Apocrine change"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Apocrine change</strong> does not increase<strong>&nbsp;</strong>the risk of cancer as it is a <strong>non-proliferative</strong> change.</p>\n<p>Moderate or florid hyperplasia, fibroadenoma with complex features, and sclerosing adenosis are classified under <strong>proliferative disease without atypia </strong>with a <strong>1.5- to 2-fold</strong> increased risk of carcinoma.</p>\n<p>Both breasts are at increased risk, although the risk to the ipsilateral breast may be slightly higher.</p><hr><h3>Related Pearl: Epithelial Lesions and Risk of Malignancy</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Pathologic Lesions and Relative Risk of Malignancy</strong></p>\n</td>\n<td>\n<p><strong>Examples&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Non-proliferative Breast Changes / Fibrocystic changes</strong></p>\n<p>(RR = 1)</p>\n</td>\n<td>\n<ul>\n<li>Duct ectasia</li>\n<li>Cysts</li>\n<li>Apocrine change</li>\n<li>Mild hyperplasia</li>\n<li>Adenosis</li>\n<li>Fibroadenoma without complex features</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Proliferative Disease Without Atypia</strong></p>\n<p>(RR = 1.5 to 2)</p>\n</td>\n<td>\n<ul>\n<li>Moderate or florid hyperplasia</li>\n<li>Sclerosing adenosis</li>\n<li>Papilloma</li>\n<li>Complex sclerosing lesion (radial scar)</li>\n<li>Fibroadenoma with complex features</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Proliferative Disease with Atypia</strong></p>\n<p>(RR = 4 to 5)</p>\n</td>\n<td>\n<ul>\n<li>Atypical ductal hyperplasia (ADH)</li>\n<li>Atypical lobular hyperplasia (ALH)</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Carcinoma in situ</strong></p>\n<p>(RR = 8 to 10)</p>\n</td>\n<td>\n<ul>\n<li>Lobular carcinoma in situ (LCIS)</li>\n<li>Ductal carcinoma in situ (DCIS)</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5674",
      "difficulty": "medium"
    },
    {
      "text": "While undergoing a routine mammogram, a 45-year-old woman was found to have clusters of microcalcification in her right breast. A needle biopsy was done and revealed the following. Which of the following markers can be used to rule out invasive disease?",
      "choices": [
        {
          "id": 1,
          "text": "ER"
        },
        {
          "id": 2,
          "text": "HER2"
        },
        {
          "id": 3,
          "text": "p53"
        },
        {
          "id": 4,
          "text": "p63"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p class=\"p1\"><span class=\"s1\">The given image is suggestive of the&nbsp;<strong>comedo</strong> type of ductal carcinoma in situ (<strong>DCIS</strong>). Myoepithelial cell markers like <strong>p63</strong> can <strong>differentiate DCIS</strong> from <strong>invasive carcinoma</strong>.</span></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/ccc4cedd6e2d420c84ef6301ba80d5ebx1280x963.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/cd8f38e081c046c29716f0aa29ff7d37x1280x962.JPEG\" alt=\"Explanation Image\"><div class=\"page\" title=\"Page 1061\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>DCIS is a malignant clonal proliferation of epithelial cells limited to ducts and lobules by the <strong>intact basement membrane</strong>. It is <strong>rarely palpable</strong> and is almost always detected by <strong>mammography</strong>.</p>\n</div>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 1061\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Myoepithelial cells</strong> (basal cell layer) are <strong>preserved</strong> in involved ducts or lobules in DCIS. Hence the myoepithelial cell markers like <strong>p63</strong>, basal cytokeratin (<strong>CK 5/6</strong>), <strong>calponin </strong>will be <strong>positive in DCIS</strong> whereas it will be absent in infiltrating ductal carcinoma.&nbsp;However, myoepithelial markers may be diminished in high-grade DCIS compared to surrounding normal ducts or lobules.</p>\n<p>Once the tumor cells penetrate through the basement membrane and grow within the stroma, they are considered to be invasive carcinoma.</p>\n</div>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/60fc5ddd85aa4e38857a3277fb3e63a0x1280x1883.JPEG\" alt=\"Explanation Image\"><p>Note:<strong>&nbsp;</strong>Lobular carcinoma in situ (<strong>LCIS</strong>) has recently been classified as a&nbsp;<strong>benign</strong>&nbsp;lesion with associated risk for developing carcinoma in the future but not as a malignancy capable of metastases.</p><hr><h3>Related Pearl: Characteristics of in situ ductal (DCIS) and lobular (LCIS) carcinoma of the breast</h3><div class=\"page\" title=\"Page 548\">\n<table><colgroup><col /><col /><col /> </colgroup>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>LCIS</strong></p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>DCIS</strong></p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Age (years)</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>44&ndash;47</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>54&ndash;58</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Incidence</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>2%&ndash;5%</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>5%&ndash;10%</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Clinical signs</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Mostly incidental finding.</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Usually asymptomatic but mass, pain, nipple discharge may also be seen.</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Mammographic signs</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>None</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Microcalcifications</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Premenopausal</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>2/3</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>1/3</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Incidence of synchronous invasive carcinoma</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>5%</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>2%&ndash;46%</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Multicentricity</strong></p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>60%&ndash;90%</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>40%&ndash;80%</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Bilaterality</strong></p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>50%&ndash;70%</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>10%&ndash;20%</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Axillary metastasis</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>1%</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>1%&ndash;2%</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Subsequent carcinomas:</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Incidence</li>\n</ul>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>25%&ndash;35%</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>25%&ndash;70%</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Laterality</li>\n</ul>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Bilateral</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ipsilateral</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Interval to diagnosis</li>\n</ul>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>15&ndash;20 y</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>5&ndash;10 y</p>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Histologic type</li>\n</ul>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ductal</p>\n</div>\n</div>\n</td>\n<td>\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Ductal</p>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n</div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/4007c1159d974bc7a4a8b7ce50dfd0be.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6688",
      "difficulty": "hard"
    },
    {
      "text": "A 55-year-old woman presents with persistent soreness and itching in her right nipple. On examination, the following finding is noted. What would be the next best step in her management?",
      "choices": [
        {
          "id": 1,
          "text": "Prescribe antibiotics"
        },
        {
          "id": 2,
          "text": "Biopsy of the nipple"
        },
        {
          "id": 3,
          "text": "Prescribe cortisone cream"
        },
        {
          "id": 4,
          "text": "Observation and follow-up"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The given scenario showing a red eczematous rash over the areola of the breast is suggestive of&nbsp;<strong>Paget's disease of the nipple</strong>. The next best step in management is <strong>biopsy</strong> of the nipple.</p>\n<p>Paget's disease <strong>can be mistaken for eczema,</strong> and hence, <strong>biopsy</strong> of the nipple should be the initial management of choice.&nbsp;Paget cells are readily detected by nipple biopsy.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/f749fa70d62444a09a90ded5f0517081.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5696",
      "difficulty": "medium"
    },
    {
      "text": "Histopathological examination of a middle-aged woman who presented with redness and itching over the nipple of her left breast is given below. Which of the following statements is incorrect about her condition?",
      "choices": [
        {
          "id": 1,
          "text": "The cells are ER positive"
        },
        {
          "id": 2,
          "text": "Underlying carcinoma is poorly differentiated"
        },
        {
          "id": 3,
          "text": "Prognosis depends on the underlying carcinoma"
        },
        {
          "id": 4,
          "text": "The cells show overexpression of HER2"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario and image showing <strong>Paget's cells</strong>&nbsp;(malignant cells with&nbsp;abundant pale cytoplasm and pleomorphic nuclei)<strong>&nbsp;</strong>are suggestive of <strong>Paget's disease</strong> of the nipple. These cells are <strong>ER-negative</strong>.</p>\n<p>Paget's disease of the nipple is a rare form of ductal carcinoma in-situ (<strong>DCIS</strong>). The characteristic Paget's cells are scattered individually throughout the squamous epithelium. They&nbsp;do not breach the basement membrane but <strong>extend</strong> via the <strong>lactiferous sinuses</strong> into the nipple <strong>skin</strong>.</p>\n<p>The following images show Paget's cells that do not breach the basement membrane.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/64572bcadadf45e7a721e9ff018f1e4fx720x578.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/acf7c2f954974629b26b3de72f6976d8x1279x1197.JPEG\" alt=\"Explanation Image\"><p>It presents as a unilateral<strong> erythematous </strong>eruption with a <strong>scale crust.</strong>&nbsp;A palpable mass is seen in about half the patients with this disease.</p>\n<p>The underlying carcinomas are usually <strong>poorly differentiated</strong>, ER-negative, and <strong>overexpress HER2</strong>. The <strong>prognosis</strong> of Paget's disease <strong>depends on</strong> the features of the <strong>underlying carcinoma</strong>.</p>\n<p>Paget's disease may mimic the following conditions:</p>\n<ul>\n<li><strong>Eczema</strong> (clinical appearance) - can be differentiated by the presence of malignant cells on biopsy</li>\n<li>Superficial spreading <strong>melanoma</strong> (histological appearance) -&nbsp;Paget's cells are PAS-positive and<strong> diastase resistant </strong>unlike melanoma cells&nbsp;</li>\n</ul>\n<p>Note: Paget's disease of the bone is a distinct condition that results in abnormal bone metabolism due to&nbsp;osteoclastic overactivity.&nbsp;</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/d7d6fb4afe8b40d39a78b3626298c17f.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5692",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a risk factor for breast cancer?",
      "choices": [
        {
          "id": 1,
          "text": "Dense breast"
        },
        {
          "id": 2,
          "text": "Post-menopausal obesity"
        },
        {
          "id": 3,
          "text": "Early pregnancy"
        },
        {
          "id": 4,
          "text": "Early menarche"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>Early full-term pregnancy (younger than 20 years) is <strong>protective</strong> against breast cancer. It<strong> halves the risk</strong>&nbsp;of developing breast cancer compared to that of nulliparous women.</p>\n<p>Women with very <strong>dense breasts</strong> on <strong>mammography</strong> have a <strong>four- to six-fold</strong> higher risk of both ER-positive and ER-negative breast cancer compared to women with low density.</p>\n<p>Obese women under the age of 40 years have a decreased risk as a result of anovulatory cycles and lower progesterone levels. In contrast, <strong>postmenopausal obese women </strong>are at&nbsp;an<strong> increased risk</strong>, which is attributed to the synthesis of estrogens in fat depots.</p>\n<p><strong>Early menarche</strong>, late menopause, and nulliparity are risk factors of breast cancer due to <strong>hyperestrogenemia</strong>. Exercise and breastfeeding are protective against breast cancer.</p><hr><h3>Related Pearl: Risk Factors and Protective Factors for Breast Carcinoma</h3><p><strong>Risk factors:</strong></p>\n<ul>\n<li>Age: Incidence increases with increasing age.</li>\n<li>Sex: more common in females.</li>\n<li>Family history of breast cancer</li>\n<li>Race, ethnicity (white women have increased risk compared to women of other races)</li>\n<li>History of radiation exposure</li>\n<li>Mammographically dense breast</li>\n<li>Genetic factors:</li>\n<li>Mutations in tumor suppressor genes:\n<ul>\n<li><em><strong>BRCA 1</strong></em></li>\n<li><em><strong>BRCA 2</strong></em></li>\n<li><em>TP53</em></li>\n<li><em>CHEK2</em></li>\n</ul>\n</li>\n<li>Hereditary syndromes:\n<ul>\n<li>Li Fraumeni syndrome</li>\n<li>Cowden&rsquo;s syndrome</li>\n<li>HNPCC syndrome</li>\n<li>Peutz-Jegher&rsquo;s syndrome</li>\n<li>Ataxia telangiectasia</li>\n</ul>\n</li>\n<li>Hormonal factors (hyperestrogenemia is the risk factor):\n<ul>\n<li>Early menarche</li>\n<li>Late menopause</li>\n<li>First full-term pregnancy &gt;30 years</li>\n<li>Nulliparity</li>\n<li>Obesity (postmenopausal)</li>\n</ul>\n</li>\n<li>Higher socioeconomic status, high fat diet, alcohol intake</li>\n</ul>\n<p><strong>Protective factors:</strong></p>\n<ul>\n<li>Early age at first pregnancy</li>\n<li>Multiparity</li>\n<li>Breastfeeding</li>\n<li>Oophorectomy</li>\n<li>Exercise</li>\n<li>Tamoxifen and Aromatase inhibitors</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5682",
      "difficulty": "easy"
    },
    {
      "text": "What is the most common site of carcinoma in the breast?",
      "choices": [
        {
          "id": 1,
          "text": "Upper inner quadrant"
        },
        {
          "id": 2,
          "text": "Upper outer quadrant"
        },
        {
          "id": 3,
          "text": "Lower outer quadrant"
        },
        {
          "id": 4,
          "text": "Subareolar region"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The<strong> upper outer quadrant </strong>is the most common site of carcinoma in the breast.</p>\n<p>Approximately 50% of carcinomas are located in the upper outer quadrant, 10% in each of the remaining quadrants, and about 20% in the central or subareolar region.</p>\n<div class=\"page\" title=\"Page 20\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>A <strong>palpable mass</strong> is the most common clinical sign of <strong>invasive breast carcinoma</strong>.</p>\n<p><strong>Triple assessment</strong>&nbsp;is recommended for the diagnosis of any palpable breast lump. It includes:&nbsp;</p>\n<ul>\n<li><strong>Clinical</strong> examination</li>\n<li><strong>Radiological</strong> assessment (mammography/USG)</li>\n<li><strong>Pathological</strong> assessment (FNAC/biopsy)</li>\n</ul>\n<p><strong>Techniques of palpation</strong> for breast examination are:</p>\n<ol>\n<li>Vertical strip/lines pattern</li>\n<li>Circular pattern</li>\n<li>Wedges or radial spokes pattern</li>\n</ol>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f291e205b3a8431ea4c4b9099ed3d902x600x1384.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5649",
      "difficulty": "easy"
    },
    {
      "text": "On which of the following chromosomes is the BRCA2 gene located?",
      "choices": [
        {
          "id": 1,
          "text": "Chromosome 13"
        },
        {
          "id": 2,
          "text": "Chromosome 11"
        },
        {
          "id": 3,
          "text": "Chromosome 17"
        },
        {
          "id": 4,
          "text": "Chromosome 12"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>BRCA2</strong> gene is located on the <strong>long arm</strong> of&nbsp;<strong>chromosome 13 </strong>(13q12.3).&nbsp;</p>\n<div class=\"page\" title=\"Page 1058\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 1058\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Mutations in BRCA1 and BRCA2 are responsible for 80 to 90% of single gene familial breast cancers and about 3% of all breast cancers.</p>\n<div class=\"page\" title=\"Page 1058\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>ER-positive, HER2-negative </strong>cancers (<strong>luminal</strong> <strong>type</strong>)&nbsp;is the most common subtype of breast cancer in individuals who inherit germline mutations in BRCA2. This&nbsp;gene is associated more frequently with <strong>male breast cancer</strong>.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div><p>Single gene mutations associated with familial breast cancer can be categorized into:</p>\n<ul>\n<li aria-level=\"1\">High penetrance germline mutations (&gt;4 fold increased risk) - <strong>BRCA1</strong>, <strong>BRCA2</strong>, TP53, PTEN, STK11, CDH I, PALPB2</li>\n<li aria-level=\"1\">Moderate penetrance germline mutations (2-4 fold increased risk) - <strong>ATM</strong>, <strong>CHEK2</strong></li>\n</ul><hr><h3>Related Pearl: Comparison between BRCA 1 and BRCA 2:</h3><div class=\"panel-body ng-scope\">\n<p>Both <em>BRCA1</em> and <em>BRCA2</em> are <strong>tumor suppressor genes.</strong></p>\n<p>Carcinoma breast <strong>occurs at an earlier age</strong> and is <strong>bilateral and multicentric in </strong>inherited forms compared to sporadic cases.</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>BRCA 1</strong></td>\n<td><strong>BRCA 2</strong></td>\n</tr>\n<tr>\n<td>Location</td>\n<td>Long arm of <strong>chromosome 17</strong>&nbsp;</td>\n<td>Long arm of <strong>chromosome 13</strong></td>\n</tr>\n<tr>\n<td>Differentiation</td>\n<td>Poorly differentiated</td>\n<td>Well-differentiated</td>\n</tr>\n<tr>\n<td>Hormone receptor status</td>\n<td>ER/PR- Negative, Her-2 negative &ndash; triple negative</td>\n<td>ER/PR- Positive</td>\n</tr>\n<tr>\n<td>Associated Cancers</td>\n<td>Breast, ovarian, colon, and prostate (lesser extent), Pancreas (lesser extent)&nbsp; cancers</td>\n<td>Breast, ovarian, colon, prostate, pancreas, gall bladder, stomach cancers, and melanoma</td>\n</tr>\n<tr>\n<td>Male breast carcinoma</td>\n<td>Low risk</td>\n<td><strong>Increased risk</strong></td>\n</tr>\n<tr>\n<td>Fanconi&rsquo;s anemia</td>\n<td>Not associated</td>\n<td>Associated</td>\n</tr>\n<tr>\n<td>Medullary carcinoma</td>\n<td>Associated</td>\n<td>Not associated</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5688",
      "difficulty": "medium"
    },
    {
      "text": "Immunohistochemical testing was performed on a biopsy sample taken from a patient with breast cancer. It revealed lack of expression of ER, PR, and HER2. Which of the following genes is most commonly mutated in this condition?",
      "choices": [
        {
          "id": 1,
          "text": "RET"
        },
        {
          "id": 2,
          "text": "MYC"
        },
        {
          "id": 3,
          "text": "TP53"
        },
        {
          "id": 4,
          "text": "PIK3CA"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given scenario is suggestive of <strong>triple-negative breast cancer</strong> (ER-negative, PR-negative, and HER2-negative). <strong>TP53</strong> is the most commonly mutated gene in triple-negative breast cancer (TNBC).</p>\n<p>Common gene mutations in the 3 major molecular types of invasive breast carcinoma are:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Molecular Subtype</strong></td>\n<td><strong>Common gene mutations</strong></td>\n</tr>\n<tr>\n<td>Luminal (ER+/HER2-)</td>\n<td>\n<p>Luminal A: PIK3CA (more common), TP53</p>\n<p>Luminal B: PIK3CA (more common), TP53</p>\n</td>\n</tr>\n<tr>\n<td>HER2 Positive (HER 2+)</td>\n<td>TP53 (more common),&nbsp;PIK3CA</td>\n</tr>\n<tr>\n<td>TNBC (ER-/ HER2-)</td>\n<td>TP53 (more common),&nbsp;PIK3CA</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5690",
      "difficulty": "medium"
    },
    {
      "text": "A 44-year-old woman has been diagnosed with breast carcinoma. Immunohistochemistry staining of a tissue biopsy specimen of this patient is given below. Which of the following statements is true regarding her condition?",
      "choices": [
        {
          "id": 1,
          "text": "BRCA 1 mutation is most probable"
        },
        {
          "id": 2,
          "text": "It is not associated with tP53 mutations"
        },
        {
          "id": 3,
          "text": "Poor response to paclitaxel"
        },
        {
          "id": 4,
          "text": "Good response to trastuzumab"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The given immunohistochemistry (IHC) staining shows&nbsp;<strong>positive ER, PR</strong>&nbsp;(brown nucleus), and <strong>negative&nbsp;</strong><strong>Her-2&nbsp;</strong>(no membrane-bound brown stain)&nbsp;expression, which is suggestive of&nbsp;<strong>luminal A </strong>molecular subtype. It shows a&nbsp;<strong>poor response</strong> to <strong>paclitaxel</strong>.</p>\n<p>Hormone receptors (<strong>ER</strong>, <strong>PR</strong>) are present in the <strong>nucleus</strong>. Therefore ER, PR&ndash;positive breast cancer cells will stain dark in the nucleus on IHC. Her-2 receptors are <strong>membrane-bound</strong> receptors, and hence, cells having these receptors are darkly stained on the membranes.&nbsp;</p>\n<p>Luminal A type is more commonly associated with&nbsp;<strong>BRCA2 </strong>mutations.&nbsp;</p>\n<p>Hormone receptor-positive tumors are <strong>responsive</strong> to hormonal chemotherapeutic&nbsp;agents like <strong>tamoxifen</strong> and<strong> aromatase inhibitors</strong>. In&nbsp;Her-2 negative cases,&nbsp;<strong>trastuzumab</strong> is not effective as it is a recombinant humanized monoclonal antibody directed <strong>against HER-2</strong>.&nbsp;</p>\n<p>The following image shows ER/ PR/ Her-2 positivity:</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a5487734d1a34540b922a6d360f48c3ax720x341.JPEG\" alt=\"Explanation Image\"><p>Note: At least <strong>10%</strong> of luminal type A breast cancers express <strong>tp53</strong> mutations. <strong>tP53</strong> mutations are associated with <strong>triple-negative</strong> tumors as well.</p><hr><h3>Related Pearl: Molecular classification of breast cancer</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Molecular subtypes&nbsp;</strong></td>\n<td>\n<p><strong>Receptor status </strong></p>\n</td>\n<td><strong>Histological subtypes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal A type&nbsp;</strong></p>\n<p><strong>(most common,&nbsp;</strong>best prognosis)</p>\n<p>Mutated gene-&nbsp;BRCA 2</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&lt;14% (low)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1069\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Lobular carcinoma</p>\n<p>Mucinous carcinoma</p>\n<p>Tubular carcinoma</p>\n<p>Papillary carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2/neu negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 2&nbsp;</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&gt;14% (high)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Poorly differentiated, lobular-carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2 positive)</strong></p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>variable</strong></p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><strong>HER2 enriched</strong></p>\n<p>Mutated gene-&nbsp;TP53</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High&nbsp;</strong></p>\n</td>\n<td>\n<p>Apocrine carcinoma</p>\n<p>Micro-papillary carcinoma</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Basal type&nbsp;</strong><strong>(Triple-negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 1</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Medullary carcinoma</p>\n<p>Adenoid cystic carcinoma</p>\n<p>Secretory carcinoma</p>\n<p>Metaplastic carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Update: <strong>Claudin low-molecular subtype</strong>&nbsp;is a triple-negative breast cancer with low expression of E-cadherin, with a poor prognosis. It is frequently associated with lymphocyte infiltration.</p>\n<p>Almost all breast malignancies are adenocarcinomas and based on the expression of estrogen receptor and HER2 can be divided into three major biologic subgroups:</p>\n<ul>\n<li><strong>ER-positive HER2-negative tumors&nbsp;</strong>(50% to 65% of tumors) &ndash; range from well-differentiated cancers with low proliferative rates and few chromosomal changes to poorly differentiated cancers with high proliferative rates and large numbers of chromosomal rearrangements. All of these cancers express ER.</li>\n<li><strong>HER2-positive cancers - </strong>10% to 20% of tumors, which may either be ER-positive or ER-negative.</li>\n<li><strong>ER-negative, HER2-negative carcinomas&nbsp;</strong>(triple-negative or basal-like)- are characterized by genomic instability, a high proliferative rate, and expression of many proteins typical of myoepithelial cells (e.g., basal keratins).</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Defining Features</strong></p>\n</td>\n<td>\n<p><strong>ER-positive, HER2- negative</strong></p>\n&nbsp;&nbsp;</td>\n<td>&nbsp;</td>\n<td>\n<p><strong>HER2- Positive (ER- positive or negative)</strong></p>\n</td>\n<td>\n<p><strong>ER- negative</strong></p>\n<p><strong>HER2- negative</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Frequency</p>\n</td>\n<td>\n<p>~40-55% (Low proliferation)</p>\n</td>\n<td>\n<p>~10% (High proliferation)</p>\n</td>\n<td>\n<p>~20%</p>\n</td>\n<td>\n<p>~15%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Included special histologic types</p>\n</td>\n<td>\n<p>Well or moderately differentiated lobular, tubular, mucinous</p>\n</td>\n<td>\n<p>Poorly differentiated lobular</p>\n</td>\n<td>\n<p>Some apocrine</p>\n</td>\n<td>\n<p>Medullary, adenoid cystic, secretory, metaplastic</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Typical patient groups</p>\n</td>\n<td>\n<p>Older women, men, cancers detected by mammographic screening</p>\n</td>\n<td>\n<p><em>BRCA2</em> mutation carriers</p>\n</td>\n<td>\n<p>Young women, non-white women, <em>TP53</em> mutation carrier (ER-positive)</p>\n</td>\n<td>\n<p>Young women, <em>BRCA1 </em>mutation carriers, African American and Hispanic women</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/7d879eb7d4604defbbddd0e5222189bd.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6630",
      "difficulty": "hard"
    },
    {
      "text": "Immunohistochemistry test of a breast cancer patient was reported negative for ER and HER2. This molecular subtype includes all of the following except:",
      "choices": [
        {
          "id": 1,
          "text": "Secretory carcinoma"
        },
        {
          "id": 2,
          "text": "Spindle cell carcinoma"
        },
        {
          "id": 3,
          "text": "Adenoid cystic carcinoma"
        },
        {
          "id": 4,
          "text": "Mucinous carcinoma"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>Carcinomas with immunohistochemistry<strong> ER and HER2/ negative</strong> are all of the above <strong>except</strong> mucinous carcinomas. Mucinous carcinomas are usually <strong>ER-positive and HER2/neu negative</strong> (luminal A type)</p>\n<p><strong>ER-negative</strong>,<strong> HER2-negative</strong> (triple-negative) molecular subtype commonly includes the following<strong>histological subtypes</strong>:</p>\n<ul>\n<li>Medullary</li>\n<li>Adenoid cystic</li>\n<li>Secretory</li>\n<li>Metaplastic</li>\n<li>Spindle cell</li>\n<li>Squamous</li>\n<li>Matrix-producing</li>\n</ul><hr><h3>Related Pearl: Molecular classification of breast cancer</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Molecular subtypes&nbsp;</strong></td>\n<td>\n<p><strong>Receptor status </strong></p>\n</td>\n<td><strong>Histological subtypes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal A type&nbsp;</strong></p>\n<p><strong>(most common,&nbsp;</strong>best prognosis)</p>\n<p>Mutated gene-&nbsp;BRCA 2</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&lt;14% (low)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1069\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Lobular carcinoma</p>\n<p>Mucinous carcinoma</p>\n<p>Tubular carcinoma</p>\n<p>Papillary carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2/neu negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 2&nbsp;</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&gt;14% (high)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Poorly differentiated, lobular-carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2 positive)</strong></p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>variable</strong></p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><strong>HER2 enriched</strong></p>\n<p>Mutated gene-&nbsp;TP53</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High&nbsp;</strong></p>\n</td>\n<td>\n<p>Apocrine carcinoma</p>\n<p>Micro-papillary carcinoma</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Basal type&nbsp;</strong><strong>(Triple-negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 1</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Medullary carcinoma</p>\n<p>Adenoid cystic carcinoma</p>\n<p>Secretory carcinoma</p>\n<p>Metaplastic carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Update: <strong>Claudin low-molecular subtype</strong>&nbsp;is a triple-negative breast cancer with low expression of E-cadherin, with a poor prognosis. It is frequently associated with lymphocyte infiltration.</p>\n<p>Almost all breast malignancies are adenocarcinomas and based on the expression of estrogen receptor and HER2 can be divided into three major biologic subgroups:</p>\n<ul>\n<li><strong>ER-positive HER2-negative tumors&nbsp;</strong>(50% to 65% of tumors) &ndash; range from well-differentiated cancers with low proliferative rates and few chromosomal changes to poorly differentiated cancers with high proliferative rates and large numbers of chromosomal rearrangements. All of these cancers express ER.</li>\n<li><strong>HER2-positive cancers - </strong>10% to 20% of tumors, which may either be ER-positive or ER-negative.</li>\n<li><strong>ER-negative, HER2-negative carcinomas&nbsp;</strong>(triple-negative or basal-like)- are characterized by genomic instability, a high proliferative rate, and expression of many proteins typical of myoepithelial cells (e.g., basal keratins).</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Defining Features</strong></p>\n</td>\n<td>\n<p><strong>ER-positive, HER2- negative</strong></p>\n&nbsp;&nbsp;</td>\n<td>&nbsp;</td>\n<td>\n<p><strong>HER2- Positive (ER- positive or negative)</strong></p>\n</td>\n<td>\n<p><strong>ER- negative</strong></p>\n<p><strong>HER2- negative</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Frequency</p>\n</td>\n<td>\n<p>~40-55% (Low proliferation)</p>\n</td>\n<td>\n<p>~10% (High proliferation)</p>\n</td>\n<td>\n<p>~20%</p>\n</td>\n<td>\n<p>~15%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Included special histologic types</p>\n</td>\n<td>\n<p>Well or moderately differentiated lobular, tubular, mucinous</p>\n</td>\n<td>\n<p>Poorly differentiated lobular</p>\n</td>\n<td>\n<p>Some apocrine</p>\n</td>\n<td>\n<p>Medullary, adenoid cystic, secretory, metaplastic</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Typical patient groups</p>\n</td>\n<td>\n<p>Older women, men, cancers detected by mammographic screening</p>\n</td>\n<td>\n<p><em>BRCA2</em> mutation carriers</p>\n</td>\n<td>\n<p>Young women, non-white women, <em>TP53</em> mutation carrier (ER-positive)</p>\n</td>\n<td>\n<p>Young women, <em>BRCA1 </em>mutation carriers, African American and Hispanic women</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5703",
      "difficulty": "medium"
    },
    {
      "text": "Patients with all of the following conditions have ER-positive and HER2-negative tumors except:",
      "choices": [
        {
          "id": 1,
          "text": "Lobular carcinoma"
        },
        {
          "id": 2,
          "text": "Tubular carcinoma"
        },
        {
          "id": 3,
          "text": "Mucinous carcinoma"
        },
        {
          "id": 4,
          "text": "Secretory carcinoma"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>ER-positive</strong>, <strong>HER2-negative</strong> status on immunohistochemistry is suggestive of the<strong>luminal type</strong> of breast carcinoma, which does not include secretory carcinoma.</p>\n<p>The ER-positive, HER2-negative molecular subtype (<strong>luminal type</strong>) commonly includes the following histological subtypes:</p>\n<ul>\n<li>Well and poorly differentiated <strong>lobular</strong> carcinoma</li>\n<li><strong>Tubular</strong> carcinoma</li>\n<li><strong>Mucinous</strong> carcinoma</li>\n<li>Papillary carcinoma</li>\n</ul>\n<p><strong>Secretory</strong> <strong>carcinomas</strong> are usually ER-negative and Her2/neu negative (<strong>basal type</strong>).</p><hr><h3>Related Pearl: Molecular classification of breast cancer</h3><p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Molecular subtypes&nbsp;</strong></td>\n<td>\n<p><strong>Receptor status </strong></p>\n</td>\n<td><strong>Histological subtypes</strong></td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal A type&nbsp;</strong></p>\n<p><strong>(most common,&nbsp;</strong>best prognosis)</p>\n<p>Mutated gene-&nbsp;BRCA 2</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&lt;14% (low)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1069\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Lobular carcinoma</p>\n<p>Mucinous carcinoma</p>\n<p>Tubular carcinoma</p>\n<p>Papillary carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2/neu negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 2&nbsp;</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>&gt;14% (high)</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Poorly differentiated, lobular-carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Luminal B type (HER2 positive)</strong></p>\n</td>\n<td>\n<p>ER/PR-&nbsp;+ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>variable</strong></p>\n</td>\n<td>&nbsp;</td>\n</tr>\n<tr>\n<td>\n<p><strong>HER2 enriched</strong></p>\n<p>Mutated gene-&nbsp;TP53</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- +ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High&nbsp;</strong></p>\n</td>\n<td>\n<p>Apocrine carcinoma</p>\n<p>Micro-papillary carcinoma</p>\n<p>&nbsp;</p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Basal type&nbsp;</strong><strong>(Triple-negative)</strong></p>\n<p>Mutated gene-&nbsp;BRCA 1</p>\n</td>\n<td>\n<p>ER/PR-&nbsp;-ve</p>\n<p>Her2- -ve</p>\n<p><strong>Ki-67-&nbsp;</strong></p>\n<p><strong>High</strong></p>\n</td>\n<td>\n<div class=\"page\" title=\"Page 1064\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Medullary carcinoma</p>\n<p>Adenoid cystic carcinoma</p>\n<p>Secretory carcinoma</p>\n<p>Metaplastic carcinoma</p>\n</div>\n</div>\n</div>\n</div>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>*Update: <strong>Claudin low-molecular subtype</strong>&nbsp;is a triple-negative breast cancer with low expression of E-cadherin, with a poor prognosis. It is frequently associated with lymphocyte infiltration.</p>\n<p>Almost all breast malignancies are adenocarcinomas and based on the expression of estrogen receptor and HER2 can be divided into three major biologic subgroups:</p>\n<ul>\n<li><strong>ER-positive HER2-negative tumors&nbsp;</strong>(50% to 65% of tumors) &ndash; range from well-differentiated cancers with low proliferative rates and few chromosomal changes to poorly differentiated cancers with high proliferative rates and large numbers of chromosomal rearrangements. All of these cancers express ER.</li>\n<li><strong>HER2-positive cancers - </strong>10% to 20% of tumors, which may either be ER-positive or ER-negative.</li>\n<li><strong>ER-negative, HER2-negative carcinomas&nbsp;</strong>(triple-negative or basal-like)- are characterized by genomic instability, a high proliferative rate, and expression of many proteins typical of myoepithelial cells (e.g., basal keratins).</li>\n</ul>\n<table>\n<tbody>\n<tr>\n<td>\n<p><strong>Defining Features</strong></p>\n</td>\n<td>\n<p><strong>ER-positive, HER2- negative</strong></p>\n&nbsp;&nbsp;</td>\n<td>&nbsp;</td>\n<td>\n<p><strong>HER2- Positive (ER- positive or negative)</strong></p>\n</td>\n<td>\n<p><strong>ER- negative</strong></p>\n<p><strong>HER2- negative</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Frequency</p>\n</td>\n<td>\n<p>~40-55% (Low proliferation)</p>\n</td>\n<td>\n<p>~10% (High proliferation)</p>\n</td>\n<td>\n<p>~20%</p>\n</td>\n<td>\n<p>~15%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Included special histologic types</p>\n</td>\n<td>\n<p>Well or moderately differentiated lobular, tubular, mucinous</p>\n</td>\n<td>\n<p>Poorly differentiated lobular</p>\n</td>\n<td>\n<p>Some apocrine</p>\n</td>\n<td>\n<p>Medullary, adenoid cystic, secretory, metaplastic</p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Typical patient groups</p>\n</td>\n<td>\n<p>Older women, men, cancers detected by mammographic screening</p>\n</td>\n<td>\n<p><em>BRCA2</em> mutation carriers</p>\n</td>\n<td>\n<p>Young women, non-white women, <em>TP53</em> mutation carrier (ER-positive)</p>\n</td>\n<td>\n<p>Young women, <em>BRCA1 </em>mutation carriers, African American and Hispanic women</p>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA6112",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following breast cancers most commonly presents as an occult primary carcinoma?",
      "choices": [
        {
          "id": 1,
          "text": "Micropapillary carcinoma"
        },
        {
          "id": 2,
          "text": "Mucinous carcinoma"
        },
        {
          "id": 3,
          "text": "Medullary carcinoma"
        },
        {
          "id": 4,
          "text": "Lobular carcinoma"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Lobular carcinoma </strong>is the most common type of breast carcinoma to present as an <strong>occult primary</strong> carcinoma.</p>\n<p>Lobular carcinoma of the breastis seen<strong> bilaterally</strong> and with <strong>multicentricity</strong>.<strong>Loss of E-cadherin </strong>is the <strong>hallmark</strong> of lobular carcinoma. They also have characteristic patterns of metastatic spread, often involving the peritoneum and retroperitoneum, leptomeninges (carcinomatous meningitis), gastrointestinal tract, ovaries, and uterus.</p>\n<p>The histological hallmark of lobular carcinoma is the presence of discohesive infiltrating tumor cells, often arranged in a<strong>single Indian file</strong><strong>pattern</strong> or in loose clusters or sheets.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/c29d7fe1ba1b4ffa921f7e1d9ed1ad43x1280x1253.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5700",
      "difficulty": "medium"
    },
    {
      "text": "Which of the following is not a feature of lobular breast carcinoma?",
      "choices": [
        {
          "id": 1,
          "text": "Often bilateral"
        },
        {
          "id": 2,
          "text": "Multicentricity within the same breast"
        },
        {
          "id": 3,
          "text": "Loss of E-cadherin"
        },
        {
          "id": 4,
          "text": "Extensive desmoplasia"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>There is <strong>no or very slight desmoplastic response </strong>seen<strong></strong>in<strong>lobular carcinomas</strong>.</p>\n<p>Desmoplasia refers to <strong>collagenous stromal proliferation</strong> induced by tumor cells which is essential for tumor growth and spread. It results in hard and stony tumors. However, this is not seen in lobular carcinoma. This is likely due to the <strong>loss</strong> <strong>of expression of CDH1</strong>, the gene that encodes<strong>e-cadherin</strong>(normally maintains intercellular adhesiveness). This also results in<strong>disaggregation</strong> of cells.</p>\n<p>Lobular carcinomas are often <strong>bilateral</strong>and <strong>multicentric</strong>. It shows characteristic <strong>metastatic spread</strong>, often involving:</p>\n<ul>\n<li>Peritoneum and retro peritoneum</li>\n<li>Leptomeninges (carcinomatous meningitis)</li>\n<li>Gastrointestinal tract</li>\n<li>Ovaries</li>\n<li>Uterus</li>\n</ul>\n<p>Histopathological image of invasive lobular carcinoma of breast showing <strong>discohesive cells</strong> with few <strong>signet ring cells</strong>.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/81c745e29c1a433b85c60766411f425ex1280x1398.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/48cd7ae153ed4a4caaa68be83a1e2eb3x1280x1399.JPEG\" alt=\"Explanation Image\"><p><strong>Note: </strong>Individuals with heterozygous germline mutations in CDH1 (<strong>loss of E-cadherin</strong>) also have a greatly increased risk of <strong>gastric signet-ring cell carcinoma</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5698",
      "difficulty": "medium"
    },
    {
      "text": "A 53-year-old woman with breast cancer is found to have TNM staging of T4dN0M0. Which of the following statements is true regarding her condition?",
      "choices": [
        {
          "id": 1,
          "text": "There is loss of e-cadherin expression"
        },
        {
          "id": 2,
          "text": "It has a relatively favorable prognosis"
        },
        {
          "id": 3,
          "text": "There is obstruction of dermal lymphatics by neoplastic cells"
        },
        {
          "id": 4,
          "text": "History of trauma to the breast is usually present"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>T4d</strong> in the TNM staging of carcinoma breast points toward a diagnosis of <strong>inflammatory breast carcinoma</strong>.&nbsp;It&nbsp;shows extensive invasion and proliferation of tumor cells within the <strong>dermal lymphatics</strong>&nbsp;leading to&nbsp;<strong>obstruction</strong>.</p>\n<p>Inflammatory breast cancer is the <strong>most aggressive </strong>subtype of breast cancer. The hallmark of this condition is the&nbsp;<strong>overexpression&nbsp;</strong>of&nbsp;<strong>e-cadherin.&nbsp;</strong>This results in increased tumor cohesion and the formation of tumoral clumps which can result in emboli. It has a&nbsp;particularly <strong>poor prognosis</strong>.</p>\n<div class=\"page\" title=\"Page 70\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>These tumors are usually of <strong>high grade</strong>&nbsp;but do not belong to any particular molecular subtype.&nbsp;More than half (60%) are <strong>ER-negative</strong> and 40% to 50% <strong>overexpress HER2</strong>. There is no association with trauma.</p>\n<p>Due to lymphatic obstruction, it results in&nbsp;brawny induration, erythema with a raised edge, and edema called&nbsp;<strong>peau d&rsquo;orange</strong> appearance. This <strong>may</strong>&nbsp;<strong>mimic&nbsp;</strong>non-neoplastic inflammatory lesions like&nbsp;<strong>mastitis</strong>.&nbsp;A breast lump may or may not be present.&nbsp;</p>\n<p>The following image shows<strong>&nbsp;</strong>a<strong>&nbsp;</strong>peau d&rsquo;orange appearance of the right breast.</p>\n</div>\n</div>\n</div><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a256683c4da546c28c6f5ed35f48c8fbx720x405.PNG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: TNM Staging of Carcinoma Breast</h3><table>\n<tbody>\n<tr>\n<td><strong>Tumor (T)</strong></td>\n<td>\n<p><strong>Description</strong></p>\n</td>\n</tr>\n<tr>\n<td>Tx</td>\n<td>\n<p>Primary tumor cannot be assessed</p>\n</td>\n</tr>\n<tr>\n<td>T0</td>\n<td>\n<p>No evidence of primary tumor</p>\n</td>\n</tr>\n<tr>\n<td><strong>Tis (DCIS)</strong></td>\n<td>Ductal carcinoma in situ</td>\n</tr>\n<tr>\n<td><strong>Tis (Paget)</strong></td>\n<td>Paget disease not associated with invasive carcinoma or DCIS</td>\n</tr>\n<tr>\n<td>T1</td>\n<td>\n<p><strong>&le;</strong><strong>2 cm</strong> in greatest dimension</p>\n<p><strong>1mic</strong>&nbsp;&le; 0.1 cm</p>\n<p>1a &gt;0.1 to 0.5 cm</p>\n<p>1b &gt;0.5 to 1 cm</p>\n<p>1c &gt;1 to 2 cm</p>\n</td>\n</tr>\n<tr>\n<td>T2</td>\n<td><strong>&gt;2 but &le;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T3</td>\n<td><strong>&gt;5 cm</strong> in greatest dimension</td>\n</tr>\n<tr>\n<td>T4</td>\n<td>\n<p>Tumor of<strong> any size&nbsp;</strong>and -</p>\n<p><strong>4a</strong> &ndash; chest wall involvement (except pectoralis major)<strong>#</strong>&nbsp;</p>\n<p><strong>4b </strong>&ndash; skin involvement in the form of ulceration, peau d&rsquo;orange, satellite nodules &nbsp;</p>\n<p><strong>4c </strong>&ndash; 4a + 4b &nbsp;</p>\n<p><strong>4d</strong> &ndash; Inflammatory breast carcinoma (typical skin changes involving <span>&gt;</span>1/3rd of breast)<strong>*</strong></p>\n</td>\n</tr>\n<tr>\n<td><strong>Nodes (N)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>N1 mic</td>\n<td>Refers to micrometastasis to Lymph node</td>\n</tr>\n<tr>\n<td>N1</td>\n<td>Ipsilateral <strong>mobile</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2A</td>\n<td>Ipsilateral<strong> fixed or matted</strong> axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N2B</td>\n<td>Ipsilateral internal mammary <strong>without axillary lymph node</strong> involvement</td>\n</tr>\n<tr>\n<td>N3A</td>\n<td>Ipsilateral infraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td>N3B</td>\n<td>Ipsilateral internal mammary and axillary lymph nodes</td>\n</tr>\n<tr>\n<td>N3C</td>\n<td>Ipsilateral supraclavicular lymph nodes</td>\n</tr>\n<tr>\n<td><strong>Distant metastasis (M)</strong></td>\n<td><strong>Description</strong></td>\n</tr>\n<tr>\n<td>M0</td>\n<td>Metastasis absent</td>\n</tr>\n<tr>\n<td>M1</td>\n<td>Metastasis present</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Stages</strong></td>\n<td><strong>T, N</strong></td>\n<td>&nbsp;<strong>M</strong></td>\n</tr>\n<tr>\n<td>Stage 0</td>\n<td>T<sub>is</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IA</td>\n<td>T<sub>1</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IB</td>\n<td>T<sub>0,1</sub>N<sub>1mic</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIA</td>\n<td>T<sub>0,1</sub>N<sub>1</sub> (or) T<sub>2</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIB</td>\n<td>T<sub>2</sub>N<sub>1</sub> (or) T<sub>3</sub>N<sub>0</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIA</td>\n<td>T<sub>0,1,2,3</sub>N<sub>2 </sub>(or) T<sub>3</sub>N<sub>1</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIB</td>\n<td><strong>T</strong><sub><strong>4</strong>&nbsp;</sub>N<sub>0,1,2</sub></td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IIIC</td>\n<td>\n<p>Any T,<strong> N<sub>3</sub></strong></p>\n</td>\n<td>M<sub>0</sub></td>\n</tr>\n<tr>\n<td>Stage IV</td>\n<td>\n<p>Any T, Any N</p>\n</td>\n<td><strong>M<sub>1</sub></strong></td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p><strong>#&nbsp;</strong>Chest wall includes Serratus anterior, Intercostal muscles, Ribs.&nbsp;Pectoralis muscle is <strong>not</strong> a part of the chest wall.</p>\n<p><strong>*&nbsp;</strong>Inflammatory breast carcinoma (stage 4d) is characterized by the skin changes of&nbsp;<strong>brawny induration, erythema</strong> with a raised edge, and edema (<strong>peaud&rsquo;orange</strong>) involving <span>&gt;</span>1/3rd of the breast.</p>\n<p>Note: LCIS (lobular carcinoma in situ) is considered a benign condition and not included under Tis.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/2202ec4c95df457eb86eaf658395ea5dx1280x943.JPEG\" alt=\"Pearl Image\"><p>Prefixes for TNM staging:</p>\n<ul>\n<li><strong>c:</strong>&nbsp;clinical staging (e.g. cT1b)</li>\n<li><strong>p:</strong>&nbsp;pathological (histological) staging</li>\n<li><strong>y:</strong>&nbsp;stage following systemic or radiation therapy (either prior to surgery or as a primary treatment)</li>\n<li><strong>r:</strong>&nbsp;staging at the time of retreatment or recurrence for disease progression</li>\n</ul>\n<p>Suffix for TNM staging:</p>\n<ul>\n<li><strong>m:</strong>&nbsp;multiple primary tumours of the same histology in the same organ, e.g. T2(m) or T2(5), the latter meaning that there are five primary tumours</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5704",
      "difficulty": "medium"
    },
    {
      "text": "Immunohistochemistry for HER2 protein expression is performed in 3 patients with breast carcinoma, with the following results. Which of the following patients should be subjected to fluorescence in-situ hybridization?",
      "choices": [
        {
          "id": 1,
          "text": "Patient A"
        },
        {
          "id": 2,
          "text": "Patient C"
        },
        {
          "id": 3,
          "text": "Patients B and C"
        },
        {
          "id": 4,
          "text": "Patients A and C"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The immunohistochemistry (IHC) pattern of&nbsp;<strong>patient C</strong>&nbsp;reveals moderately strong circumferential staining (faint brown color) in &gt;10 % of cells, which is classified as <strong>2+</strong> or <strong>equivocal</strong> staining. Hence, she should be subjected to fluorescence in situ hybridization (<strong>FISH</strong>) to <strong>confirm</strong> <strong>HER2-positive</strong>&nbsp;gene amplification status.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e7eadae9aaf1403399eadaa2ef3cc625x1280x1252.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/4cb27d72e8614595ae8b4e0ce2a8d0dex1280x1323.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/5d1f88f168044be7a084c2f861fe2a7cx1280x1322.JPEG\" alt=\"Explanation Image\"><p>The following are classified as <strong>HER2-positive tumors</strong>:</p>\n<ul>\n<li>Tumors that show <strong>3+</strong> staining on IHC (here <strong>FISH</strong> is <strong>not needed</strong>).</li>\n<li>Tumors with 2+ staining on IHC, followed by HER2-gene amplification confirmed by FISH</li>\n</ul>\n<p>Once HER2-positive status is confirmed, targeted therapy against HER2 can be initiated with <strong>trastuzumab</strong> or <strong>lapatinib</strong>.&nbsp;</p><hr><h3>Related Pearl: Newer molecular tests in breast cancer</h3><p>Newer molecular tests for breast cancer have been developed, which help in predicting the advantage of adding <strong>chemotherapy</strong>.&nbsp;These are:</p>\n<ul>\n<li>Oncotype Dx (21-geneassay)</li>\n<li>Mammaprint (70-gene assay)</li>\n<li>EndoPredict (12-gene assay)</li>\n<li>PAM50 (50-gene assay)</li>\n</ul>\n<p><strong>Oncotype Dx </strong>can only be used in<strong> hormone (ER, PR) receptor-positive&nbsp;cancers, </strong>while <strong>mammaprint </strong>can be used in<strong> both </strong>hormone receptor (ER, PR) positive&nbsp;and hormone receptor-negative&nbsp;cancers.&nbsp;</p>\n<p>These tests are used for T<sub>1,2 </sub>N<sub>0</sub> M<sub>0</sub> breast cancers &ndash; (<strong>node-negative, metastasis-negative</strong>). Using these molecular tests, a <strong>recurrence score</strong> (0 &ndash; 100) is calculated.</p>\n<ul>\n<li>If the score is <strong>low</strong>, then there <strong>is no advantage</strong> of adding chemotherapy</li>\n<li>If the score is <strong>high</strong>, then chemotherapy should be <strong>added</strong></li>\n</ul>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/4a0f5ca3d9de45089698a89e77d04c36.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC6248",
      "difficulty": "medium"
    },
    {
      "text": "A middle-aged woman is diagnosed with low-grade mucinous carcinoma of the breast. IHC showed HER2 overexpression and a low Ki67 index. Which of the following would be considered as a poor prognostic factor?",
      "choices": [
        {
          "id": 1,
          "text": "Low grade"
        },
        {
          "id": 2,
          "text": "Low Ki67 index"
        },
        {
          "id": 3,
          "text": "Her2 overexpression"
        },
        {
          "id": 4,
          "text": "Mucinous carcinoma"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>HER2 overexpression</strong>&nbsp;in a patient with carcinoma breast is associated with <strong>poor survival</strong>.</p>\n<p>The main importance of HER2 status is as a <strong>predictor of response to agents</strong> that target this receptor.</p>\n<p>Prognostic and predictive factors in breast carcinoma:</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>Good prognosis</strong></td>\n<td><strong>Bad prognosis</strong></td>\n</tr>\n<tr>\n<td><strong>Extent and spread</strong></td>\n<td>\n<p>In situ carcinoma</p>\n</td>\n<td>Invasive carcinoma\n<p>Locally advanced disease</p>\n<p>Lymphovascular invasion</p>\n<p>Distant metastasis</p>\n</td>\n</tr>\n<tr>\n<td><strong>Size</strong></td>\n<td>Size &lt;1 cm</td>\n<td>Size &gt;2 cm</td>\n</tr>\n<tr>\n<td><strong>Histological subtype</strong></td>\n<td>\n<p>Tubular carcinoma</p>\n<p><strong>Mucinous carcinoma</strong></p>\n<p>Lobular carcinoma</p>\n<p>Papillary carcinoma</p>\n<p>Adenoid cystic carcinoma</p>\n</td>\n<td>\n<p>Metaplastic carcinoma</p>\n<p>Micropapillary carcinoma</p>\n</td>\n</tr>\n<tr>\n<td><strong>Histologic grade</strong></td>\n<td><strong>Low grade</strong></td>\n<td>High grade</td>\n</tr>\n<tr>\n<td><strong>Molecular subtype</strong></td>\n<td>Luminal A subtype</td>\n<td>Her2-enriched and basal subtype</td>\n</tr>\n<tr>\n<td><strong>Proliferation rate </strong>(Ki67 index &amp; mitotic counts)</td>\n<td><strong>Low proliferation rate</strong></td>\n<td>High proliferation rate</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5705",
      "difficulty": "medium"
    },
    {
      "text": "A 30-year-old woman on cyclosporin-A following renal transplantation developed multiple bilateral breast lumps that regressed after cessation of treatment. Her biopsy finding is shown below. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Fat necrosis"
        },
        {
          "id": 2,
          "text": "Phyllodes tumour"
        },
        {
          "id": 3,
          "text": "Fibroadenoma"
        },
        {
          "id": 4,
          "text": "Sclerosing adenosis"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>This clinical scenario and image showing <strong>duct proliferation</strong> are suggestive of<strong>fibroadenomas.</strong>The use of <strong>cyclosporin-A</strong> after transplantation is associated with fibroadenomas that <strong>regress</strong> after cessation of the treatment.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/59706c2784594562a658aa87182c4b16x1280x1154.JPEG\" alt=\"Explanation Image\"><p>Fibroadenomas are the <strong>most common benign tumor</strong> of the female breast. Nearly 2/3 cases are associated with mutations in the<span data-sheets-value=\"{&quot;1&quot;:2,&quot;2&quot;:&quot;Based on the update from the 10th edition of Robins, Two-thirds of fibroadenomas harbor driver mutations in MED12. The pathogenesis of the remainder is uncertain. &quot;}\" data-sheets-userformat=\"{&quot;2&quot;:829,&quot;3&quot;:{&quot;1&quot;:0},&quot;5&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;6&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;7&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;8&quot;:{&quot;1&quot;:[{&quot;1&quot;:2,&quot;2&quot;:0,&quot;5&quot;:{&quot;1&quot;:2,&quot;2&quot;:0}},{&quot;1&quot;:0,&quot;2&quot;:0,&quot;3&quot;:3},{&quot;1&quot;:1,&quot;2&quot;:0,&quot;4&quot;:1}]},&quot;11&quot;:4,&quot;12&quot;:0}\"><strong>MED12 gene</strong>.</span></p>\n<p>They are frequently <strong>multiple</strong> and <strong>bilateral</strong> and usually occur in women <strong>&lt;30 years</strong> of age. They are solid, well-defined, highly mobile masses (also known as <strong>breast mice</strong>).</p>\n<p>Fibroadenomas can be classified into 2 types:</p>\n<ul>\n<li>Without complex features - classified as a non-proliferative condition</li>\n<li>With <strong>complex features</strong> -\n<ul>\n<li>Associated with<strong>cysts</strong> &gt; 0.3 cm, <strong>sclerosing adenosis</strong>, epithelial <strong>calcifications</strong>, or papillary <strong>apocrine change</strong></li>\n<li>Classified asproliferative changes without atypia</li>\n</ul>\n</li>\n</ul><hr><h3>Related Pearl: Epithelial Lesions and Risk of Malignancy</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Pathologic Lesions and Relative Risk of Malignancy</strong></p>\n</td>\n<td>\n<p><strong>Examples&nbsp;</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Non-proliferative Breast Changes / Fibrocystic changes</strong></p>\n<p>(RR = 1)</p>\n</td>\n<td>\n<ul>\n<li>Duct ectasia</li>\n<li>Cysts</li>\n<li>Apocrine change</li>\n<li>Mild hyperplasia</li>\n<li>Adenosis</li>\n<li>Fibroadenoma without complex features</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Proliferative Disease Without Atypia</strong></p>\n<p>(RR = 1.5 to 2)</p>\n</td>\n<td>\n<ul>\n<li>Moderate or florid hyperplasia</li>\n<li>Sclerosing adenosis</li>\n<li>Papilloma</li>\n<li>Complex sclerosing lesion (radial scar)</li>\n<li>Fibroadenoma with complex features</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Proliferative Disease with Atypia</strong></p>\n<p>(RR = 4 to 5)</p>\n</td>\n<td>\n<ul>\n<li>Atypical ductal hyperplasia (ADH)</li>\n<li>Atypical lobular hyperplasia (ALH)</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td>\n<p><strong>Carcinoma in situ</strong></p>\n<p>(RR = 8 to 10)</p>\n</td>\n<td>\n<ul>\n<li>Lobular carcinoma in situ (LCIS)</li>\n<li>Ductal carcinoma in situ (DCIS)</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/85be1ad826824ed0b1929fb36fce2c70.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5708",
      "difficulty": "medium"
    },
    {
      "text": "A 58-year-old woman presented with a large, rapidly growing painless breast lump. On examination, a smooth, multinodular breast lump was noticed. Microscopic examination of the core biopsy sample is shown below. Which of the following is an incorrect statement regarding this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Lymphatic spread is rare"
        },
        {
          "id": 2,
          "text": "Stromal cellularity is increased next to the epithelium"
        },
        {
          "id": 3,
          "text": "Absence of epithelial elements suggests malignancy"
        },
        {
          "id": 4,
          "text": "Both epithelial and stromal components can metastasize"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The given clinical scenario and image are suggestive of <strong>phyllodes tumor</strong>. Here, <strong>o</strong><strong>nly </strong>the<strong> stromal component </strong>is involved in<strong> metastasis</strong>.&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/94b8d72885fe4266ab30e00cf6853627x1280x1153.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/e634d489478f456f8c268ce427283a16x1280x1276.JPEG\" alt=\"Explanation Image\"><p>Phyllodes tumor is&nbsp;a fibroepithelial tumor arising from the<strong> intralobular stroma</strong>. It presents as a smooth,&nbsp;<strong>rapidly growing</strong>, multinodular, <strong>painless</strong> breast lump that is usually palpable. It most commonly presents in the 6th decade of life and is associated with:</p>\n<ul>\n<li>Gain in chromosome 1q</li>\n<li>HOXB13 overexpression</li>\n</ul>\n<p>Phyllodes tumors show&nbsp;<strong>stromal</strong> <strong>cellularity</strong> next to the epithelium (<strong>subepithelial </strong>or<strong> periepithelial&nbsp;</strong>regions). This feature helps to&nbsp;differentiate it from intracanalicular fibroadenoma.</p>\n<p>The prognosis of phyllodes tumors depends on their histological grade. Most phyllodes tumors are low grade, with limited stromal cellularity. They recur only occasionally and do not metastasize.</p>\n<p>The features of <strong>malignant</strong>&nbsp;(intermediate and high grade) phyllodes tumors are:</p>\n<ul>\n<li>Markedly increased stromal cellularity</li>\n<li>Stromal overgrowth -&nbsp;<strong>absence</strong> of <strong>epithelial elements&nbsp;</strong></li>\n<li>Nuclear atypia</li>\n<li>Increased mitosis (&gt;10/ 10 hpf)&nbsp;</li>\n<li>Highly recurrent</li>\n</ul>\n<p>Regardless of the grade,<strong> lymphatic spread</strong> is <strong>rare</strong> in phyllodes tumors. Hence, axillary lymph node dissection is contraindicated.</p>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/572ace13db5d45b0a4fbde9d1aa20fa0.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5709",
      "difficulty": "medium"
    },
    {
      "text": "What is the most common stromal malignancy in the breast?",
      "choices": [
        {
          "id": 1,
          "text": "Leiomyosarcoma"
        },
        {
          "id": 2,
          "text": "Liposarcoma"
        },
        {
          "id": 3,
          "text": "Angiosarcoma"
        },
        {
          "id": 4,
          "text": "Fibrosarcoma"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p><strong>Angiosarcoma </strong>is the most common stromal malignancy in the breast.</p>\n<p>It arises in the <strong>interlobular stroma</strong> and accounts for &lt; 0.05% of breast malignancies. It is a <strong>high-grade</strong> tumor with a<strong>poor prognosis</strong>.It can either be sporadic or occur in association with <strong>radiation therapy</strong>.The mean age of affected individuals is <strong>35 years</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MA5710",
      "difficulty": "hard"
    },
    {
      "text": "BRCA-2 mutation does not predispose to the development of which of the following conditions?",
      "choices": [
        {
          "id": 1,
          "text": "Renal cell carcinoma"
        },
        {
          "id": 2,
          "text": "Male breast cancer"
        },
        {
          "id": 3,
          "text": "Prostate cancer"
        },
        {
          "id": 4,
          "text": "Pancreatic cancer"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p><strong>BRCA-2 mutation</strong> does not predispose to the development of renal cell carcinoma.</p>\n<p>BRCA-2 mutation predisposes to the development of&nbsp;<strong>prostate</strong> and <strong>pancreatic</strong>&nbsp;cancer. It is also associated with an increased risk of <strong>male breast cancer</strong>.</p><hr><h3>Related Pearl: Comparison between BRCA 1 and BRCA 2:</h3><div class=\"panel-body ng-scope\">\n<p>Both <em>BRCA1</em> and <em>BRCA2</em> are <strong>tumor suppressor genes.</strong></p>\n<p>Carcinoma breast <strong>occurs at an earlier age</strong> and is <strong>bilateral and multicentric in </strong>inherited forms compared to sporadic cases.</p>\n<table>\n<tbody>\n<tr>\n<td>&nbsp;</td>\n<td><strong>BRCA 1</strong></td>\n<td><strong>BRCA 2</strong></td>\n</tr>\n<tr>\n<td>Location</td>\n<td>Long arm of <strong>chromosome 17</strong>&nbsp;</td>\n<td>Long arm of <strong>chromosome 13</strong></td>\n</tr>\n<tr>\n<td>Differentiation</td>\n<td>Poorly differentiated</td>\n<td>Well-differentiated</td>\n</tr>\n<tr>\n<td>Hormone receptor status</td>\n<td>ER/PR- Negative, Her-2 negative &ndash; triple negative</td>\n<td>ER/PR- Positive</td>\n</tr>\n<tr>\n<td>Associated Cancers</td>\n<td>Breast, ovarian, colon, and prostate (lesser extent), Pancreas (lesser extent)&nbsp; cancers</td>\n<td>Breast, ovarian, colon, prostate, pancreas, gall bladder, stomach cancers, and melanoma</td>\n</tr>\n<tr>\n<td>Male breast carcinoma</td>\n<td>Low risk</td>\n<td><strong>Increased risk</strong></td>\n</tr>\n<tr>\n<td>Fanconi&rsquo;s anemia</td>\n<td>Not associated</td>\n<td>Associated</td>\n</tr>\n<tr>\n<td>Medullary carcinoma</td>\n<td>Associated</td>\n<td>Not associated</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>\n<p>&nbsp;</p>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MC5490",
      "difficulty": "medium"
    },
    {
      "text": "A 35-year-old woman presents with a lump in the upper outer quadrant of her breast. Histopathological examination of the mass showed cells in mucin pools and faint nuclei. What is the most likely diagnosis?",
      "choices": [
        {
          "id": 1,
          "text": "Colloid carcinoma"
        },
        {
          "id": 2,
          "text": "Papillary carcinoma"
        },
        {
          "id": 3,
          "text": "Medullary carcinoma"
        },
        {
          "id": 4,
          "text": "Lobular carcinoma"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p class=\"p2\">The given scenario is suggestive of <strong>colloid or mucinous</strong> <strong>carcinoma</strong> of the breast.</p>\n<p class=\"p2\">Colloid carcinoma is an <strong>invasive</strong> breast carcinoma, which shows intracellular and extracellular<strong> mucin deposition</strong>.</p>\n<p class=\"p2\">On histopathological examination, <strong>extracellular</strong> <strong>type</strong> shows tumor cells with faint nuclei, arranged in clusters, floating in&nbsp;lakes or <strong>pools of mucin</strong>. In <strong>intracellular</strong> <strong>type</strong>, nuclei are pushed to the periphery to form a&nbsp;<strong>signet ring </strong>appearance.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/a831220b913e403db15a907a1b52f9a8x1280x1142.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/65cca367fb6b4cb998cf9db0b09db25ax1280x1142.JPEG\" alt=\"Explanation Image\"><p class=\"p1\">Option B: Microscopic image of <strong>papillary carcinoma</strong> of the breast showing true papillae with a <strong>leaf-like arrangement</strong> of fibrovascular tissue lined by the tumor cells is shown below.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/96d19a43136f49a38104a1cb77bcf09bx1280x1049.JPEG\" alt=\"Explanation Image\"><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/618a4a7601e84fe996c2ca3e543c30b8x1280x1048.JPEG\" alt=\"Explanation Image\"><p class=\"p1\">Option C: Microscopic image of <strong>medullary carcinoma</strong> of the breast consisting of sheets of highly pleomorphic cells with mitotic figures (anaplastic cells), <strong>lymphoplasmacytic infiltrate</strong>&nbsp;is shown below.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/529378204b254d588fea2cc28b5cf5fax1280x1224.JPEG\" alt=\"Explanation Image\"><p>Option D: Microscopic image of <strong>lobular carcinoma</strong> of the breast shows infiltrating small monomorphic discohesive tumor cells arranged in an&nbsp;<strong>Indian-file </strong>or <strong>single-file pattern</strong>&nbsp;is shown below.</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/6c534f79aec54514a03858d5601eeedex1280x1253.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MD0785",
      "difficulty": "medium"
    }
  ]
}